Effect of postchemotherapy nausea and vomiting on health-related quality of life

Supportive Care in Cancer

Volumn 5, Issue 4, 1997, Pages 307-313

  Osoba, David ^a,f   Zee, Benny ^b   Warr, David ^c   Latreille, Jean ^d   Kaizer, Leonard ^e   Pater, Joseph ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e CREDIT VALLEY HOSPITAL   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cancer; Chemotherapy; Nausea; Quality of life; Vomiting

Indexed keywords

ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; VOMITING;

ANALYSIS OF VARIANCE; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; VOMITING;

EID: 0030741838     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050078     Document Type: Article

References (20)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 85:365-376
2. Berry WR, House KW, Lee JT, Plagge PB, Meshad MW, Grapski R, et al (1992) Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy. Semin Oncol 19 [Suppl 15]:33-37
3. Canadian Pharmaceutical Association (1996) Stemetil. Compendium of pharmaceuticals and specialities. CPA, Ottawa, p 1388
4. Clavel M, Soukop M, Greenstreet YL (1993) Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 50:180-185
5. Coates A, Abraham S, Kaye S, Sowerbutts T, Frewin C, Fox RM, et al (1983) On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208
6. Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, et al (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute on Canada Clinical Trials Group. J Clin Oncol 12:1050-1057
7. Laslo J (1983) Nausea and vomiting as major complications of cancer chemotherapy. Drugs 25:1-7
8. Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, et al (1995) Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer 3:307-312
9. Levine AM, Richardson JL, Marks G, Chan K, Graham J, Selser JN, et al (1987) Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 5:1469-1476
10. Lindley CM, Bernard S, Fidds SM (1989) Incidence and duration of chemotherapy induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142-1149
11. Lindley CM, Hirsch JD, O'Neil CV, Transau MC, Gilbert CS, Osterhaus JT, et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
12. O'Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, et al (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and costs: survey of five Canadian centres. Can Med Assoc J 149:296-302
13. Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J (1994) Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364
14. Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J (1996) Quality of life studies in chemotherapy-induced emesis. Oncology 53 [Suppl 1]:92-95
15. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Derterminants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15.116-123
16. Richardson JL, Marks G, Levine A (1988) The influence of symptoms of disease and side effects of treatment on compliance with therapy. J Clin Oncol 6:1746-1752
17. Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring quality of life of cancer patients: the Functional Living Index - Cancer: development and validation. J Clin Oncol 2:472-483
18. 3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 73:445-454
19. Steel RGD, Torrie JH (1960) Principles and procedures of statistics, 2nd edn. McGraw-Hill, New York
20. Willan AR, Warr D, Pater JL, et al (1991) Methodological issues and antiemetic studies. In: Osoba D (ed) Effect of cancer quality of life. CRC Press, Boca Raton, Fla, pp 229-249